Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer.

Adriana Camargo CarvalhoFrederico LealAndré Deeke Sasse

Published in: PloS one (2017)

Our economic evaluation demonstrates that both cetuximab and panitumumab are not a cost-effective approach in RAS-wt mCRC patients. Discussion about drug price should be prioritized to enable incorporation of these monoclonal antibodies in the SUS.

Keyphrases

metastatic colorectal cancer
wild type
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
emergency department
electronic health record
patient reported